|
2014 Journal Article Transient MEK inhibitor-associated retinopathy in metastatic melanomaUrner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Moutouh-de Parseval, L., Dummer, R. and Goldinger, S. M. (2014). Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Annals of Oncology, 25 (7), 1437-1441. doi: 10.1093/annonc/mdu169 |
|
2014 Journal Article To B-(RAF) or Not to BeDummer, Reinhard, Goldinger, Simone M., Widmer, Daniel, Dreier, Jil and Levesque, Mitchell P. (2014). To B-(RAF) or Not to Be. Journal of Investigative Dermatology, 134 (5), 1200-1201. doi: 10.1038/jid.2014.62 |
|
2014 Conference Publication Differential influence of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical efficacy in melanomaSchilling, B., Sondermann, W., Zhao, F., Griewank, K., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J. C., Kaehler, K. C., Utikal, J., Al Ghazal, P., Gutzmar, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2014). Differential influence of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical efficacy in melanoma. 41st Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung (ADF), Cologne Germany, Mar 13-15, 2014. HOBOKEN: WILEY. |
|
2014 Journal Article Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaSchilling, B., Sondermann, W., Zhao, F., Griewank, K. G., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kahler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2014). Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology, 25 (3), 747-753. doi: 10.1093/annonc/mdt587 |
|
2014 Journal Article Vemurafenib in patients with <i>BRAF<SUP>V600</SUP></i> mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot studyDummer, Reinhard, Goldinger, Simone M., Turtschi, Christian P., Eggmann, Nina B., Michielin, Olivier, Mitchell, Lada, Veronese, Luisa, Hilfiker, Paul Rene, Felderer, Lea and Rinderknecht, Jeannine D. (2014). Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. European Journal of Cancer, 50 (3), 611-621. doi: 10.1016/j.ejca.2013.11.002 |
|
2014 Journal Article The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic MelanomaVan Allen, Eliezer M., Wagle, Nikhil, Sucker, Antje, Treacy, Daniel J., Johannessen, Cory M., Goetz, Eva M., Place, Chelsea S., Taylor-Weiner, Amaro, Whittaker, Steven, Kryukov, Gregory V., Hodis, Eran, Rosenberg, Mara, McKenna, Aaron, Cibulskis, Kristian, Farlow, Deborah, Zimmer, Lisa, Hillen, Uwe, Gutzmer, Ralf, Goldinger, Simone M., Ugurel, Selma, Gogas, Helen J., Egberts, Friederike, Berking, Carola, Trefzer, Uwe, Loquai, Carmen, Weide, Benjamin, Hassel, Jessica C., Gabriel, Stacey B., Carter, Scott L. ... Schadendorf, Dirk (2014). The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discovery, 4 (1), 94-109. doi: 10.1158/2159-8290.CD-13-0617 |
|
2014 Journal Article Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsGoldinger, Simone M., Zimmer, Lisa, Schulz, Carsten, Ugurel, Selma, Hoeller, Christoph, Kaehler, Katharina C., Schadendorf, Dirk, Hassel, Jessica C., Becker, Juergen, Hauschild, Axel and Dummer, Reinhard (2014). Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 50 (2), 406-410. doi: 10.1016/j.ejca.2013.09.014 |
|
2013 Conference Publication Differential effects of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical effectivity in melanomaSchilling, B., Suttorp, W., Zhao, F., Griewank, K., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kaehler, K., Utikal, J., Gutzmer, R., Al Ghazal, P., Goldinger, S., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2013). Differential effects of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical effectivity in melanoma. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication Hyponatraemia and Tachyarrhythmia During Ipilimumab: Lessons from the AutopsyMurer, C., Goldinger, S. M., Maggio, Marques E., Bjasch, D., Stieger, P., Mihic-Probst, D., Schad, K. and Dummer, R. (2013). Hyponatraemia and Tachyarrhythmia During Ipilimumab: Lessons from the Autopsy. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication Registry for advanced melanoma in SwitzerlandMangana, J., Frauchiger, A., Goldinger, S. M., Gautschi, M., Von Moos, R., Romano, E., Michielin, O., Levesque, M. P. and Dummer, R. (2013). Registry for advanced melanoma in Switzerland. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsGoldinger, Simone M., Murer, Carla, Stieger, Pascale and Dummer, Reinhard (2013). Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2013 Conference Publication The genetic landscape of clinical resistance to RAF inhibition in melanomaVan Allen, Eliezer Mendel, Wagle, Nikhil, Carter, Scott L., Sucker, Antje, Farlow, Deborah Norman, Hodis, Fran, Taylor-Weiner, Amara, Berking, Carola, Egberts, Friederike, Hassel, Jessica Cecile, Gogas, Helen, Gutzmer, Ralf, Goldinger, Simone M., Loquai, Carmen, Ugurel, Selma, Zimmer, Lisa, Gabriel, Stacey B., Getz, Gad, Garraway, Levi A. and Schadendorf, Dirk (2013). The genetic landscape of clinical resistance to RAF inhibition in melanoma. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2013 Conference Publication Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?Mangana, Joanna, Goldinger, Simone M., Schindler, Katja, Rozati, Sima, Frauchiger, Anna L., Rechsteiner, Markus, Moch, Holger, Romano, Emanuela, Kaehler, Katharina C., Michielin, Olivier, Hauschild, Axel, Hoeller, Christoph and Dummer, Reinhard (2013). Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2013 Conference Publication The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkHeinzerling, L., Goldinger, S. M., Voskens, C. J., Loquai, C., Robert, C., Berking, C., Eigentler, T., Fluck, M., Garbe, C., Gutzmer, R., Gleiss, H., Hauschild, A., Hein, R., Justich, A., Keller, U., Klein, C., Mateus, C., Mohr, P., Paetzold, S., Satzger, , Schadendorf, D., Schlaeppi, M., Ulrich, J., Vaubel, J., von Moos, R., Weder, P., Wilhelm, T., Kaehler, K., Goeppner, D. ... Schuler, G. (2013). The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Journal Article RASopathic Skin Eruptions during Vemurafenib TherapyRinderknecht, Jeannine D., Goldinger, Simone M., Rozati, Sima, Kamarashev, Jivko, Kerl, Katrin, French, Lars E., Dummer, Reinhard and Belloni, Benedetta (2013). RASopathic Skin Eruptions during Vemurafenib Therapy. Plos One, 8 (3) e58721. doi: 10.1371/journal.pone.0058721 |
|
2013 Journal Article Melanoma immunotherapy: historical precedents, recent successes and future prospectsRaaijmakers, Marieke I. G., Rozati, Sima, Goldinger, Simone M., Widmer, Daniel S., Dummer, Reinhard and Levesque, Mitchell P. (2013). Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy, 5 (2), 169-182. doi: 10.2217/IMT.12.162 |
|
2013 Journal Article The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkVoskens, Caroline J., Goldinger, Simone M., Loquai, Carmen, Robert, Caroline, Kaehler, Katharina C., Berking, Carola, Bergmann, Tanja, Bockmeyer, Clemens L., Eigentler, Thomas, Fluck, Michael, Garbe, Claus, Gutzmer, Ralf, Grabbe, Stephan, Hauschild, Axel, Hein, Ruediger, Hundorfean, Gheorghe, Justich, Armin, Keller, Ullrich, Klein, Christina, Mateus, Christine, Mohr, Peter, Paetzold, Sylvie, Satzger, Imke, Schadendorf, Dirk, Schlaeppi, Marc, Schuler, Gerold, Schuler-Thurner, Beatrice, Trefzer, Uwe, Ulrich, Jens ... Heinzerling, Lucie M. (2013). The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. Plos One, 8 (1) e53745. doi: 10.1371/journal.pone.0053745 |
|
2012 Journal Article Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8<SUP>+</SUP> T-cell responses in melanoma patientsGoldinger, Simone M., Dummer, Reinhard, Baumgaertner, Petra, Mihic-Probst, Daniela, Schwarz, Katrin, Hammann-Haenni, Anya, Willers, Joerg, Geldhof, Christine, Prior, John O., Kuendig, Thomas M., Michielin, Olivier, Bachmann, Martin F. and Speiser, Daniel E. (2012). Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients. European Journal of Immunology, 42 (11), 3049-3061. doi: 10.1002/eji.201142361 |
|
2012 Journal Article From chemotherapy to targeted treatmentDummer, R., Rozati, S., Eggmann, N., Rinderknecht, J. and Goldinger, S. M. (2012). From chemotherapy to targeted treatment. Annals of Oncology, 23, 101-103. doi: 10.1093/annonc/mds308 |
|
2012 Conference Publication OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM)Dummer, R., Goldinger, S., Turtschi, C., Eggmann, N., Michielin, O., Mitchell, L., Veronese, L., Hilfiker, P. R. and Rinderknecht, J. D. (2012). OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM). 37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna Austria, Sep 28-Oct 02, 2012. OXFORD: OXFORD UNIV PRESS. |
